Scandinavian Micro Biodevices Due Diligence
Run due diligence on Scandinavian Micro Biodevices: check compliance and get alerts when suppliers or ownership change.
Denmark · owned by Technolution (Netherlands) · smpt.dk · 5 vendors
A contract development and manufacturing organization (CDMO) for microfluidic-based consumables, specializing in Lab-on-a-Chip (LOAC) products.
Resilience scores
- Digital Sovereignty: 20
- Digital Resilience: 3
- Financial Resilience: 7
Technology vendors
- Hotjar Ltd — Technology — Malta
- The Rocket Science Group LLC (Intuit Mailchimp) — Media & Marketing — United States
- WP Engine, Inc. — Technology — United States
- and 2 more
Insights
Last updated 2026-09-13 · revision 29
5 direct vendors, 112 subvendors
Direct vendors by controlling owner country (sample)
- United States: 4
- France: 1
Subvendors by controlling owner country (sample)
- China: 1
- Germany: 2
- Sweden: 4
Compliance
6 in-scope frameworks identified; showing 3.
GDPR (source) — No public evidence
GDPR is universally applicable to all EU-based companies that process personal data, which includes virtually all business operations (employee data, customer data, supplier data). As a Danish company, GDPR compliance is mandatory.
ISO 27001 (source) — No public evidence
ISO 27001 is not legally mandatory but is industry best practice for information security management. For pharmaceutical CDMOs handling sensitive intellectual property and potentially regulated data, ISO 27001 certification is often expected by customers and may be required for certain contracts.
EU MDR — No public evidence
As a biodevices CDMO, EU MDR likely applies if they manufacture medical devices or components.
Financials
Three-year financials
- 2025: gross profit DKK 52.6M, EBIT DKK 11.2M, equity DKK 89.4M
- 2024: gross profit DKK 49.0M, EBIT DKK -29.3M, equity DKK 77.0M
- 2023: gross profit DKK 44.9M, EBIT DKK -1.11M, equity DKK 105M
Financial Resilience Score: 7/10
SMPT's moderately high resilience stems from its niche market position in microfluidics for diagnostics, protecting it from generalist competition. The CDMO model diversifies client risk, as success isn't tied to a single end-product. Sticky customer relationships, fostered by lengthy design and validation processes, create long-term, stable revenue streams. Operational longevity since 2003 indicates a sustainable business model, and ISO 13485 certification provides a competitive advantage in attracting healthcare clients. However, weaknesses exist. Customer concentration, common in CDMOs, means the loss of a major client could significantly impact financials. The business requires substantial and ongoing investment in cleanrooms and equipment, potentially straining cash flow. SMPT's ultimate success depends on its clients' products succeeding in the market and gaining regulatory approval.
Key strengths: Niche Market Position, Diversified Client Risk, Sticky Customer Relationships, Operational Longevity, Regulatory Compliance
Risk factors: Customer Concentration, Capital Intensity, Dependence on Client Success
Revenue by geography
- Europe: 50%
- North America: 40%
- Rest of World: 10%
Revenue by product/service
- Volume Manufacturing: 80%
- Development & Prototyping Services: 20%
Workforce by country
- Denmark: 95
- Other Countries: 5
Signed-in users can see whether their own company is exposed to this vendor's disruption, plus the full sub-vendor list and country breakdowns, every in-scope compliance framework plus gaps and next steps, and alerts when any of it changes.